Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial

The Lancet Neurology

Volumn 7, Issue 1, 2008, Pages 41-49

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DONEPEZIL; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; CAREGIVER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENTAL CAPACITY; MENTAL HEALTH; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RETINA MACULA HEMORRHAGE; SEIZURE; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; VAGINA BLEEDING; WELLBEING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES;

EID: 37449014503     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70293-4     Document Type: Article

References (63)

1. Knapp M., and Prince M. Dementia UK-a report into the prevalence and cost of dementia prepared by the Personal Social Services Research Unit (PSSRU) at the London School of Economics and the Institute of Psychiatry at King's College London, for the Alzheimer's Society (2007), Alzheimer's Society, London
2. Wimo A., Winblad B., and Jönsson L. An estimate of the worldwide societal costs of dementia in 2005. Alzheimers Dement 3 (2007) 81-91
3. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363 (2004) 2105-2115
4. McShane R., Areosa S.A., and Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2 (2006) CD003154.
5. Molnar F., Man-Son-Hing M., St John P., et al. Subcortical vascular dementia: survey of treatment patterns and research considerations. Can J Neurol Sci 25 (1998) 320-324
6. Dennis M., and Boyle A. Management of cognitive impairment of vascular origin. Psychiatr Bull R Coll Psychiatr 22 (1998) 285-287
7. Broe G., Grayson D., Creasey H., et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57 (2000) 1586-1591
8. in't Veld B., Launer L., Breteler M., Hofman A., and Stricker B. Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiol Rev 24 (2002) 248-268
9. Henderson A., Jorm A., Christensen H., Jacomb P., and Korten A. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 12 (1997) 926-930
10. Stewart W., Kawas C., Corrada M., and Metter E. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
11. Nilsson S., Johansson B., Takkinen S., et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged ≥80 year. Eur J Clin Pharmacol 59 (2003) 313-319
12. Landi F., Cesari M., Onder G., Russo A., Torre S., Bernabei R., and for the Silvernet-HC Study group. Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiatry 11 (2003) 179-185
13. Thomas T., Nadackal T., and Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport 12 (2001) 3263-3267
14. Harris J. In vitro fibrillogenesis of the amyloid β1-42 peptide: cholesterol potentiation and aspirin inhibition. Micron 33 (2002) 609-626
15. Tortosa E., Avila J., and Perez M. Acetylsalicylic acid decreases tau phosphorylation at serine 422. Neurosci Lett 396 (2006) 77-80
16. Skovronsky D., Lee V., and Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 276 (2001) 17036-17043
17. Pratico D., and Trojanowski J. Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets?. Neurobiol Aging 21 (2000) 383-421
18. Jellinger K. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109 (2005) 813-836
19. Stewart R. Cardiovascular factors in Alzheimer's disease. J Neurol Neurosurg Psychiatry 65 (1998) 143-147
20. Tatemichi T., Paik M., Bagiella E., et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 44 (1994) 1885-1891
21. Skoog I., Lernfelt B., Landahl S., et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996) 1141-1145
22. Hoffman A., Ott A., Breteler M., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 349 (1997) 151-154
23. Ott A., Breteler M., de Bruyne M., et al. Atrial fibrillation and dementia in a population based study. The Rotterdam Study. Stroke 28 (1997) 316-321
24. Ott A., Stolk R., van Harskamp F., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53 (1999) 1937-1942
25. Skoog I., Kalaria R., and Breteler M. Vascular factors and Alzheimer's disease. Alzheimer Dis Assoc Disord 13 (1999) s106-s114
26. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 4 (2000) 202-207
27. Kivipelto M., NGandu T., Fratiglioni L., et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimers disease. Arch Neurol 62 (2005) 1556-1560
28. Purandare N., Burns A., Daly K., et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study. BMJ 332 (2006) 1119-1122
29. Devine M., and Rands G. Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis. Int J Geriatr Psychiatry 18 (2003) 425-431
30. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324 (2002) 71-86
31. Meyer J., Rogers R., McClintic K., et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia-a pilot study. J Am Geriatr Soc 37 (1989) 549-555
32. Rands G., Orrel M., and Spector A. Aspirin for vascular dementia. Cochrane Database Syst Rev 4 (2000) CD001296.
33. de Abajo F., and Rogríguez L.G. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 1 (2001) 1
34. Derry S., and Loke Y. Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ 321 (2000) 1183-1187
35. Roderick P., Wilkes H., and Meade T. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 35 (1993) 219-226
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn (DSM4) (1994), American Psychiatric Association, Washington, DC
37. Folstein M., Folstein S., and McHugh P. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
38. Bucks R., Ashworth D., Wilcock G., and Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 25 (1996) 113-120
39. Cummings J., Mega M., Gray K., Rosenberg-Thompson S., Carusi D., and Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
40. Goldberg D., and Williams P. A user's guide to the general health questionnaire (1988), NFER-Nelson, Windsor
41. Lavori P. Clinical trials in psychiatry: should protocol deviation censor patient data?. Neuropsychopharmacology 6 (1992) 39-48
42. Diggle P., Heagerty P., Liang K.-Y., and Zeger S. The analysis of longitudinal data (2002), Oxford University Press, Oxford
43. Peto R., Pike M., Armitage P., et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35 (1977) 1-39
44. FDA. Peripheral and central nervous system drugs advisory committee meeting July 7, 1989 (1989), Department of Health and Human Service, Public Health Service, Food and Drug Administration, Rockville, MD
45. Burback D., Molnar F., St John P., and Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer disease therapy. Minimal clinically important difference, sample size and trial design. Dement Geriatr Cogn Disord 10 (1999) 534-540
46. Byrne L., Wilson P., Bucks R., Hughes A., and Wilcock G. The sensitivity of change over time of the Bristol activities of daily living scale in Alzheimer's disease. Int J Geriatr Psychiatry 15 (2000) 656-661
47. Mega M., Masterman D., O'Connor S., Barclay T., and Cummings J. The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56 (1999) 1388-1393
48. Kaufer D., Cummings J., and Christine D. Effect of tacrine on behavioural symptoms in Alzheimer disease: an open-label study. J Geriatr Psychiatry Neurol 9 (1996) 1-6
49. Kang J., Cook N., Manson J., et al. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ 334 (2007) 987
50. Crome P., Wijayawardhana P., Guy L., Flanagan R., and Streete P. Salicylate pharmacokinetics after single and multiple doses of Nu-Seals aspirin (300 mg) in young and elderly male and female volunteers. Drug Invest 3 (1991) 252-257
51. Diener H., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
52. Scharf S., Mander A., Ugoni A., et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 (1999) 197-201
53. SM Sainati, Ingram DM, Talwalker S, et al. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. In: Proceedings of the sixth international Stockholm/Springfield symposium on advances in Alzheimer therapy. Stockholm, 2000: 180 (abstr).
54. Aisen P., Schafer K., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
55. Reines S., Block G., Morris J., et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (2004) 66-71
56. Couzin J. Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 306 (2004) 1673-1675
57. Thal L., Ferris S., Kirby L., et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (2005) 1204-1215
58. Kalaria R., and Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13 suppl 3 (1999) S115-S123
59. Cordonnier C., van der Flier W., Sluimer J., et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 66 (2006) 1356-1360
60. Nakata-Kudo Y., Mizuno T., Yamada K., et al. Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 22 (2006) 8-14
61. Atri A., Locascio J., Lin J., et al. Prevalence and effects of lobar microhemorrhages in early-stage dementia. Neurodegener Dis 2 (2005) 305-312
62. Koennecke H. Cerebral microbleeds on MRI: prevalence, associations and potential clinical implications. Neurology 66 (2006) 165-171
63. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296 (1988) 313-316